Transbronchial lung biopsy for the diagnosis of lymphangioleiomyomatosis: the severity of cystic lung destruction assessed by the modified Goddard scoring system as a predictor for establishing the diagnosis

Shouichi Okamoto 1,2*, Kazuhiro Suzuki 2,3, Takuo Hayashi 2,4, Keiko Muraki 1, Tetsutaro Nagaoka 1, Koichi Nishino 1,2, Yasuhiro Sekimoto 1,2, Shinichi Sasaki 5, Kazuhisa Takahashi 1 and Kuniaki Seyama 1,2

Abstract

Background: A guide of patient selection for establishing the diagnosis of lymphangioleiomyomatosis (LAM) by transbronchial lung biopsy (TBLB) has not been established, although the pathological confirmation of LAM by lung biopsy is desirable, particularly when patients have no additional test results except typical findings of computed tomography (CT) of the chest.

Methods: We retrospectively reviewed the medical records of LAM patients who visited at our hospital from January 2010 to September 2018. We found 19 patients who underwent TBLB and collected the following data to investigate which parameters could predict the TBLB diagnostic positivity for LAM: age, degree of exertional dyspnea, pulmonary function test, cystic lung destruction visually assessed by the modified Goddard scoring system (MGS), serum level of vascular endothelial growth factor-D, and TBLB-related data.

Results: The diagnosis of LAM was established by TBLB in 15 of 19 patients (78.9%) and no serious complications occurred. MGS was significantly higher in the TBLB-positive group than the TBLB-negative group. In LAM patients without pulmonary lymphatic congestion on CT (N = 16), multivariable logistic regression analysis revealed that MGS and FEV1/FVC were independent contributing parameters for TBLB diagnostic positivity. However, the analysis of Bayesian inference demonstrated that MGS is a better predictor than FEV1/FVC; the probability of establishing diagnosis exceeds 80% if MGS is > 2 (i.e., area of cystic destruction occupies > 25% of lung parenchyma on CT).

Conclusions: MGS may be a helpful and convenient tool to select candidates for TBLB to establish the diagnosis of LAM pathologically.

Keywords: Bronchoscopy, Lymphangioleiomyomatosis, Modified Goddard scoring system, Transbronchial lung biopsy
Introduction

Lymphangioleiomyomatosis (LAM) is a systemic neoplastic disease that is associated with diffuse cystic lung destruction caused by proliferation and infiltration of smooth muscle-like cells (i.e., LAM cells) [1–3]. LAM mostly affects women of childbearing age and occurs both in a non-heritable form and with tuberous sclerosis complex (TSC) [4]. Dyspnea on exertion, cough, hemoptysis, and chylothorax develop with progression of the disease and recurrent pneumothoraces are common [5, 6].

The characteristic findings of computed tomography (CT) of the chest in LAM are multiple, round and thin-walled cysts presenting with diffuse distribution in the bilateral lungs. This CT appearance is pathognomonic and essential for the diagnosis of LAM [7]. However, pathological confirmation of LAM by lung biopsy is desirable to establish the diagnosis, particularly when patients have no additional diagnostic clues besides typical CT appearance. Furthermore, pathological confirmation of LAM by lung biopsy is recommended before pharmacologic therapy with sirolimus begins in patients for whom the disease was established only by pathognomonic CT appearance.

In an official American Thoracic Society (ATS) and the Japanese Respiratory Society (JRS) clinical practice guideline, transbronchial lung biopsy (TBLB) is conditionally recommended as a less invasive method than surgical lung biopsy when the histopathological diagnosis of LAM is needed [8]. However, appropriate guidelines of patient selection for TBLB have not been determined because of the rarity of this disease. From a pathological point of view, LAM cell nests are usually detected along the walls of lung cysts, in visceral pleura, and in peribronchovascular lesions in the lungs. The increase of cyst burden on CT appearance is well known to correlate with the disease severity that is represented by the deterioration of pulmonary function variables such as forced expiratory volume in 1 s (FEV₁) and diffusing capacity for carbon monoxide (DLco) [9, 10]. Accordingly, the profusion of cysts on CT appearance reasonably implicates parenchymal LAM burden and therefore it is expected to result in high diagnostic yield when TBLB is performed.

We hypothesized that the modified Goddard scoring system, which uses visual evaluation to assess the degree of cystic lung destruction, could be instrumental to predict the probability of successfully establishing the diagnosis of LAM by TBLB. In this study, we retrospectively reviewed medical records of LAM patients who underwent TBLB to establish the diagnosis of LAM pathologically, and then analyzed the correlation between the diagnostic yield and the modified Goddard scores.

Methods

From January 2010 to September 2018, 355 patients with LAM who visited at Juntendo University Hospital. All patients were diagnosed according to the diagnostic criteria of the Japanese Respiratory Society [11]. Of these patients, we retrospectively evaluated the medical records of 19 LAM patients who underwent TBLB, chest CT, and pulmonary function tests in our hospital. The following data were extracted: gender, age, the score of the modified Medical Research Council (mMRC) dyspnea scale, smoking history, serum level of vascular endothelial growth factor-D (VEGF-D) before TBLB (measured by an enzyme-linked immunosorbent assay [R&D Systems, Minneapolis, MN, USA]), the presence of extrapulmonary LAM, results of pulmonary function tests, chest CT images, and TBLB-related data (i.e., the number of biopsied specimens, and the associated complications).

Bronchoscopy was performed by pulmonologists using a flexible bronchoscope (Olympus BF 1 T260, Olympus Corporation, Shinjuku-ku, Tokyo, Japan) following local anesthesia with 2% lidocaine. TBLB was conducted from the lower, to middle, to upper lobes in order, with the use of biopsy forceps; at least 2 samples were obtained from each lobe if applicable. TBLB was performed under fluoroscopic guidance.

Biopsied specimens were evaluated by pathologists who had experience with LAM. The histopathological diagnosis of LAM was confirmed based on the presence of foci of LAM cells by hematoxylin and eosin staining, as well as immunohistochemical reactivity with melanoma-associated antigen gp100 (stained by monoclonal antibody clone HMB45), α-smooth muscle actin, and either estrogen or progesterone receptors.

Evaluation of the severity of cystic lung destruction using the modified Goddard scoring system

Chest CT scans were performed in the supine position with the breath held at full inspiration. Although all examinations of chest CT were performed before TBLB, the CT images of 2 patients had been preserved as X-ray films whereas only digital data were used for the remaining 17 patients. Analyses of chest CT scans in these 2 patients were conducted with digital CT images 3 years after TBLB. The thickness of CT slices in 15 patients was 2 mm, considered high-resolution CT (HRCT), and 5 mm in the remaining 4 patients.

The degree of cystic lung destruction was visually assessed independently by 2 pulmonologists (S.O. and K.S.) and 1 radiologist (K.S.) according to the modified Goddard scoring system [12]. Briefly, 6 images from 3 slice levels (upper, middle, lower in bilateral lung fields) per patient were analyzed and the degree of cystic destruction was scored as follows: normal (score = 0), ≤ 5% affected (score = 0.5), ≤ 25% affected (score = 1), ≤ 50% affected (score = 2), ≤ 75% affected (score = 3), and > 75% affected (score = 4). An average score of all 6 images was calculated as the modified Goddard score (MGS) for each patient. Kendall’s coefficient of concordance for
MGS assessed by 3 observers was 0.838 ($P < 0.001$), indicating high inter-observer reliability.

**Statistical analysis**
All statistical analyses were performed using R, version 3.4.1. Categorical variables were compared using Fisher’s exact test. The Mann-Whitney test was used to compare non-parametric variables. Student's t-test was used to compare parametric variables. The correlations between MGS and pulmonary function were examined by Spearman rank correlation test. A multivariable logistic regression was conducted to predict the establishment of diagnosis by TBLB, including MGS and clinical parameters in the model. A $P$ value of less than 0.05 was considered significant.

To deduce the probability of the TBLB diagnostic positivity assumed by data on MGS or FEV$_1$/forced vital capacity (FVC), we performed Bayesian inference using Stan via the rstan (Version 2.18.2) interface, compiled on C++. Stan uses the No-U-Turn Sampler which extends a type of Markov Chain Monte Carlo (MCMC) algorithm known as Hamiltonian Monte Carlo (HMC) sampling [13]. We used a MCMC chain with 10,000 iterations using the first 1000 as burn-in, which were pooled to represent the posterior distributions of parameter values. A Bernoulli distribution was assumed for the posterior probability distribution and a non-informative uniform distribution for the prior distribution.

**Results**
**Patient characteristics**
Patient characteristics of all 19 LAM patients are shown in Table 1. The diagnosis of LAM was established by TBLB in 15 of 19 patients (78.9%); thus, the foci of LAM cells was successfully demonstrated in 15 patients (TBLB-positive group) but not in the remaining 4 patients (TBLB-negative group). All patients were female sporadic LAM cases and none of them had a mMRC dyspnea scale score ≥ 3. Five TBLB-positive patients were ex-smokers; each pack-years was 1.4, 3.5, 6, 7 and 34, respectively.

The chest CT images of all patients demonstrated characteristic CT features of LAM. Two TBLB-positive and 1 TBLB-negative patient showed lymphatic congestion as illustrated in Fig. 1. The serum VEGF-D level was not significantly different between TBLB-positive and -negative groups.

We found that MGS was significantly higher in the TBLB-positive group than the TBLB-negative group (Table 1). For the full study sample (N = 19), MGS was significantly negatively correlated with FEV$_1$% of the predicted volume (%pred) ($P = 0.034$, $r = -0.49$) and DLco %pred ($P = 0.022$, $r = -0.52$), but was not significantly related to either vital capacity (VC) %pred or log (VEGF-D) (Fig. S1, Supplementary Information)). Since MGS is a visual assessment of cystic destruction, we excluded 3 LAM patients who had pulmonary lymphatic congestion from analyzing the association between TBLB results and various clinical parameters including MGS. In the remaining group of 16 LAM patients, we found that MGS was significantly negatively correlated only with DLco %pred ($P < 0.005$, $r = -0.79$) (Fig. 2).

**Diagnosis of LAM by TBLB**
The TBLB procedure was performed from the right lung in 17 patients and the left lung in 2 patients. A total of 92 tissue specimens were biopsied from the 19 patients during the TBLB procedures. No significant difference was found between TBLB-positive and -negative groups; the median number of biopsied specimens was 5 (range 3–6) in the positive group vs. 5.5 (range 4–6) in the negative group ($P = 0.427$).

No other serious events such as pneumothorax or pneumonia occurred in the full study sample. Two patients had transient fevers within 1 day after bronchoscopy. Two episodes of bleeding with moderate severity occurred after biopsy but both were managed with topical endobronchial application of epinephrine.

To identify potential clinical parameters predicting the TBLB diagnostic positivity for LAM, we performed a multivariable logistic regression analysis, incorporating DLco %pred, FEV$_1$/FVC, FEV$_1$ %pred, log (VEGF-D), and MGS in the model. In LAM patients without pulmonary lymphatic congestion on chest CT (N = 16), the TBLB diagnostic positivity for LAM was significantly influenced by MGS ($P = 0.018$) and FEV$_1$/FVC ($P = 0.006$) independently (data not shown).

Next, to validate which parameter, MGS or FEV$_1$/FVC, is more suitable to predict TBLB diagnostic positivity for LAM, we estimated the probability of diagnostic positivity generated by HMC sampling based on data from the LAM patients without lymphatic congestion on chest CT (N = 16). As shown in Table 2, the probability of TBLB diagnostic positivity was estimated to increase when MGS increased. Similarly, the distribution of sampling plots showed that the direction of increase or decrease of TBLB diagnostic positive spots was identical to that of MGS (Fig. 3). In concordance with the estimation that the probability of TBLB positivity was more than 0.832 in the levels of MGS > 2 (Table 2), almost all TBLB-positive patients had MGS > 2 (Table 1). FEV$_1$/FVC was also able to estimate the TBLB-diagnostic positivity for LAM (Table S1, Supplementary Information). However, the distribution of sampling plots showed weaker correlations with the change in FEV$_1$/FVC as compared with the change in MGS (Fig. S2, Supplementary Information)). Accordingly, we concluded that MGS was a more suitable predictor than FEV$_1$/FVC.
Discussion

Our retrospective study found that MGS, a score representing visual assessment of cystic destruction in the lungs of LAM patients, may be a reliable predictor for establishing histopathological diagnosis of LAM by TBLB. The probability of TBLB diagnostic positivity was estimated to increase or decrease proportionally with the level of MGS; the probability of establishing histopathological diagnosis exceeded 80% if MGS was > 2 (i.e., area of cystic destruction occupied > 25% of lung parenchyma on CT). In our analysis of the full study sample, MGS was significantly negatively correlated with FEV1%pred and DLco %pred, representing the disease severity of LAM [5, 14]. Furthermore, multivariable logistic regression analysis identified both MGS and FEV1/FVC as independently contributing parameters to TBLB diagnostic positivity. However, the analysis of Bayesian inference by HMC sampling revealed that MGS is a better predictor for establishing the diagnosis of LAM by TBLB than FEV1/FVC.

TBLB is a less invasive method than video-associated thoracoscopic surgery-guided lung biopsy; the complication and the mortality rates are 2.1% vs. 9.6–19.1 and 0.004% vs. 1.5–4.4%, respectively [15–18]. Therefore, the

| Table 1 Characteristics of the study sample |
|----------------------------------------------|
|                                              |
| Total (N = 19)                               |
| TBLB positive (N = 15)                        |
| TBLB negative (N = 4)                         |
| **Age** 41 (29–58)                            |
| **mMRC score** 2/12/5                         |
| 0/1/2                                        |
| **Smoking history†**                          |
| never                                        |
| 14                                          |
| ex-smoker                                    |
| 5                                           |
| Serum VEGF-D (pg/mL)                         |
| 2324.7 (457.3–5932.1)                        |
| 3138.8 (516.9–5932.1)                        |
| 2213.6 (457.3–2324.7)                        |
| **Extrapulmonary LAM lesions‡**              |
| 11                                           |
| 8                                            |
| 3                                            |
| **Pulmonary function tests**                 |
| VC (%pred)                                   |
| 101.7 (77.3–126.4)                           |
| 101.7 (77.3–126.4)                           |
| 96.8 (79.8–105.4)                            |
| FEV1 (%pred)                                 |
| 64.8 (37.6–89.0)                             |
| 62.0 (37.6–89.0)                             |
| 66.7 (59.3–81.1)                             |
| FEV1/FVC (%)                                 |
| 73.4 (35.4–103.4)                            |
| 71.1 (35.4–103.4)                            |
| 81.8 (70.0–90.3)                             |
| DLco (%pred)                                 |
| 36.3 (20.9–65.9)                             |
| 36.3 (20.9–65.9)                             |
| 38.5 (20.9–65.9)                             |
| MGS                                          |
| 2.72 (0.92–3.61)                             |
| 2.72 (1.17–3.61)                             |
| 2.08 (0.92–2.89)                             |
| **P value**                                  |
| 0.928                                        |
| 0.219                                        |
| 0.263                                        |
| 0.603                                        |
| 0.460                                        |
| 0.539                                        |
| 0.307                                        |
| 0.980                                        |
| 0.017                                        |
| **Values are presented as counts, median values (range)** |
| † Each pack-years is 1.4, 3.5, 6, 7 and 34 |
| ‡ Extrapulmonary LAM includes lymphangioleiomyoma of the mediastinum, retroperitoneum, and pelvis |

Abbreviations: DLco, diffusing capacity of carbon monoxide; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; LAM, lymphangioleiomyomatosis; MGS, modified Goddard score; mMRC, modified Medical Research Council; TBLB, transbronchial lung biopsy; VC, vital capacity; VEGF-D, vascular endothelial growth factor-D; %pred, % of the predicted volume

*Fig. 1* The representative image of a LAM patient with pulmonary lymphatic congestion. Computed tomography of the chest showing small nodules, irregularly increased parenchymal densities, thickening of interlobular septa, a major fissure and peribronchovascular interstitium in the right lower lung, and increased parenchymal densities in the lingula of the left lung. We obtained 6 biopsied specimens from the right lung by TBLB and established the diagnosis of LAM. The MGS of this patient were 0.833 and 1.17, respectively. Abbreviations: LAM, lymphangioleiomyomatosis; MGS, modified Goddard score; TBLB, transbronchial lung biopsy.
Fig. 2  Relationships between MGS and clinical parameters in 16 LAM patients without pulmonary lymphatic congestion. A, VC %pred; B, FEV1%pred; C, FEV1/FVC; D, DLco %pred; and E, log (VEGF-D). MGS was significantly negatively correlated with DLco %pred (D). Abbreviations: DLco, diffusing capacity of carbon monoxide; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; LAM, lymphangioleiomyomatosis; log (VEGF-D), logarithmic value of serum vascular endothelial growth factor-D (pg/ml); MGS, modified Goddard score; VC, vital capacity; %pred, percentage of the predicted value.

Table 2  The probability of TBLB diagnostic positivity for LAM by level of MGS

| MGS level | Probability of diagnostic positivity for LAM | 95% credible interval |
|-----------|---------------------------------------------|-----------------------|
| 3 < MGS ≤ 4 | 0.910                                       | 0.897–0.921           |
| 2 < MGS ≤ 3 | 0.832                                       | 0.816–0.847           |
| 1 < MGS ≤ 2 | 0.606                                       | 0.586–0.626           |
| 0 < MGS ≤ 1 | 0.393                                       | 0.373–0.413           |

The data was generated by Hamiltonian Monte Carlo sampling based on data from 16 LAM patients without lymphatic congestion. 95% credible interval shows the 2.5 and 97.5% percentiles of distribution. Abbreviations: LAM, lymphangioleiomyomatosis; MGS, modified Goddard score; TBLB, transbronchial lung biopsy.
Conclusions
In conclusion, we found that MGS was significantly associated with the definitive diagnosis of LAM by TBLB. Therefore, the MGS may be an effective and convenient tool that will help clinicians select candidates for TBLB to establish histopathological diagnosis of LAM. Patients with MGS between 2 and 3 (i.e., cystic destruction occupying between 25 and 75% of lung parenchyma), have a high probability of establishing a diagnosis with an acceptable risk of complications.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13023-020-01409-5.

Additional file 1: Fig. S1 Relationships between MGS and clinical parameters in LAM patients (N = 19). Fig. S2 The distribution of FEV1/FVC...
Abbreviations
ATS: American Thoracic Society; CT: Computed tomography; DLco: Diffusing capacity for carbon monoxide; FEV₁: Forced expiratory volume in 1 s; FVC: Forced vital capacity; HMC: Hamiltonian Monte Carlo; HRTCT: High-resolution computed tomography; JRS: Japanese Respiratory Society; LAM: Lymphangioleiomyomatosis; MCMC: Markov Chain Monte Carlo; MGS: Modified Goddard score; mNRC: Modified Medical Research Council; TBLB: Transbronchial lung biopsy; TSC: Tuberous sclerosis complex; VC: Vital capacity; VEGF-D: Vascular endothelial growth factor-D

Acknowledgements
We thank Kenji Shimizu for his thoughtful assistance with statistical analysis. We also thank Ms. Elaine Blumberg for her excellent proofreading and editing of English.

Authors’ contributions
SO: study design, collecting patients’ data, data analysis, and manuscript writing. KS (Suzuki): study design and radiology evaluation on the patients. TH: data analysis and histological examination of the patients. KM: study design and collecting patients’ data. TN: clinical evaluation of the patients. KN: data analysis. YS: data analysis. SS: writing-review and editing. KT: writing-review and editing. KS (Seyama): study design, manuscript writing and editorial supervision. All authors read and approved the final manuscript.

Funding
No funding was received.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
This study was approved by the Institutional Review Board at the Juntendo University School of Medicine (No.19-113).

Consent for publication
Consent for publication was obtained from all patients.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Division of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, 3-1-3 Hongo, Bunkyo-ku, Tokyo, Japan.
2 The Study Group for Pneumothorax and Cystic Lung Diseases, 4-8-1 Seta, Setagaya-ku, Tokyo, Japan.
3 Division of Radiology, Juntendo University Faculty of Medicine and Graduate School of Medicine, 3-1-3 Hongo, Bunkyo-ku, Tokyo, Japan.
4 Division of Human Pathology, Juntendo University Faculty of Medicine and Graduate School of Medicine, 3-1-3 Hongo, Bunkyo-ku, Tokyo, Japan.
5 Division of Respiratory Medicine, Juntendo Urayasu Hospital, 2-1-1 Tomioka Urayasu-shi, Chiba, Japan.

Received: 29 December 2019 Accepted: 14 May 2020
Published online: 26 May 2020

References
1. Henske EP, McCormack FX. Lymphangioleiomyomatosis: a wolf in sheep’s clothing. J Clin Invest. 2012;122(11):3807–16.
2. Seyama K, Kumasaka T, Kunihara M, Mitani K, Sato T. Lymphangioleiomyomatosis: a disease involving the lymphatic system. Lymphat Res Biol. 2010;8(1):21–31.
3. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–60.
4. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355(13):1346–56.
5. Johnson SR, Tattersfield AE. Clinical experience of lymphangioleiomyomatosis in the Uk. Thorax. 2000;55(12):1052–7.
6. Young LR, Almoosa KF, Pollock-Baziv S, Coutinho M, McCormack FX, Sahn SA. Patient perspectives on management of pneumothorax in lymphangioleiomyomatosis. Chest. 2006;129(3):1267–73.
7. Johnson SR, Cordier JE, Lazor R, Cotton V, Costabel U, Harari S, et al. European respiratory society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J. 2010;35(1):14–26.
8. Gupta N, Finlay GA, Kotloff RM, Strange C, Wilson KC, Young LR, et al. Lymphangioleiomyomatosis diagnosis and management: high-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. An official american thoracic society/japanese respiratory society clinical practice guideline. Am J Respir Crit Care Med. 2017;196(10):1337–48.
9. Clauser LM, Roque RL, Armstrong M, Touraine JL, Cunningham RS. Transbronchial lung biopsy (TBLB) in patients with lymphangioleiomyomatosis. Ann Intern Med. 1999;131(1):31–9.
10. Avila NA, Kelly JA, Dwyer AJ, Johnson DL, Jones EC, Moss J. Lymphangioleiomyomatosis: correlation of qualitative and quantitative thin-section ct with pulmonary function tests and assessment of dependence on pleuropulmonary. Radiology. 2002;223(1):189–97.
11. Hayashida M, Seyama K, Inoue Y, Hira L, Mishima M. Respiratory failure research G, Japanese Ministry of Health, welfare. [criteria for designation of lymphangioleiomyomatosis in the specified disease treatment research program]. Nihon Kokyuki Gakkai Zasshi. 2011;49(2):67–74.
12. Akita H, Nasahara Y, Nagai K, Ito Y, Hasegawa M, Betsuyaku T, et al. Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. Thorax. 2007;62(11):932–7.
13. Annis J, Miller BJ, Palmeri TJ. Bayesian inference with stan: a tutorial on adding custom distributions. Behav Res Methods. 2017;49(3):863–86.
14. Kitaichi M, Nishimura K, Itto H, Iumi T. Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am J Respir Crit Care Med. 1995;151(1 Pt 1):1527–33.
15. Asano F, Aoe M, Ohsaki Y, Okada Y, Sasada S, Sato S, et al. Deaths and complications associated with respiratory endoscopy: a survey by the Japan society for respiratory endoscopy in 2010. Respirology. 2012;17(3):478–85.
16. Kreider ME, Hansen-Flaschen J, Ahmad NN, Rosman MD, Kaiser LR, Kucharzuk JC, et al. Complications of video-assisted thoracoscopic lung biopsy in patients with interstitial lung disease. Ann Thorac Surg. 2007;83(3):1140–4.
17. Nguyen W, Meyer KC. Surgical lung biopsy for the diagnosis of interstitial lung disease: a review of the literature and recommendations for optimizing safety and efficacy. Sarcoidosis Vas Diffuse Lung Dis. 2013;30(1):1–16.
18. Durheim MT, Kim S, Gulack BC, Burfend WR, Gaisser HT, Kosinski AS, et al. Mortality and respiratory failure after thoracoscopic lung biopsy for interstitial lung disease. Ann Thorac Surg. 2017;104(2):465–70.
19. Naaldun A, Jonshon B, Foerster A, Kolbenstvedt A. When to suspect and how to diagnose pulmonary lymphangioleiomyomatosis. Respir Med. 1996;90(3):207–12.
20. Harari S, Torre O, Castandoni R, Taveira-DaSilva AM, Moss J. Bronchoscopic diagnosis of langerhans cell histiocytosis and lymphangioleiomyomatosis. Respir Med. 2012;106(9):1286–92.
21. Meraj R, Wikenheiser-Brokamp KA, Young LR, Byrnes S, McCormack FX. Utility of transbronchial biopsy in the diagnosis of lymphangioleiomyomatosis. Front Med. 2012;6(4):395–405.
22. Koba T, Ara T, Kitaichi M, Kasai T, Hirose M, Tachibana K, et al. Efficacy and safety of transbronchial lung biopsy for the diagnosis of lymphangioleiomyomatosis: a report of 24 consecutive patients. Respiropy. 2018;13(3):333–5.
23. Ye L, Jin M, Bai C. Clinical analis of patients with pulmonary lymphangioleiomyomatosis (plam) in mainland China. Respir Med. 2010;104(10):1521–6.
24. Rittrawat W, Sompradeekul S. Diagnostic yield of fluoroscopy-guided transbronchial lung biopsy in non-endobronchial lung lesion. J Med Assoc Thail. 2007;90(Suppl 2):688–73.
25. Oxt DE, Ernst A, Lei X, Kovitz KL, Benzuaen S, Diaz-Mendoza J, et al. Diagnostic yield and complications of bronchoscopy for peripheral lung lesions. Results of the aquire registry. Am J Respir Crit Care Med. 2016;193(1):687–.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.